Cellular Fibronectin -testi

Yleistä

Fibronectins (Fns) are large glycoproteins present in both insoluble form in extra cellular matrix (ECM) and soluble form in various body fluids. The insoluble form is called cellular fibronectin (cFn) and the soluble form plasma fibronectin (pFn).

Fibronectins have a role in various phenomena such as cellular differentiation, tissue organization, cell adhesion, blood coagulation and wound healing, as well as tumor invasion and metastasis.


The Cellular Ficronectin Kit is for research use only

Benefits of the test

• Marker for reactive conditions
• High sensivity of detection
• Easy to use and automate
• Reported helpful as stroke follow-up treatment
  

Lääketieteellinen tausta

Fibronectins (Fns) are large glycoproteins present in both insoluble form in extra cellular matrix (ECM) and soluble form in various body fluids. The insoluble form is called cellular fibronectin (cFn) and the  soluble form plasma fibronectin (pFn).

Cellular Fibronectin (cFn) in EDTA plasma is a marker for:

• Tumors (non-specific)
• Risk of vascular complications, especially in diabetes
• Risk of stroke recurrence
• Safety of thrombolytic therapy in stroke

.
Elevated levels of cFn in plasma have been shown to be associated with increased risk of hemorrhagic transformation after treatment with tissue plasminogen activator (t-PA) 

Cellular Fibronectin (cFn) in cervicovaginal fluid is a marker for

• Risk of premature birth

Tilaus

Lisätietoa

References:
1. Ruoslahti E. Fibronectin and its receptors. Ann Rev Biochem 1988; 57:375- 413
2. Ylätupa S, Haglund C, Mertaniemi P et al. Cellular fibronectin in serum and plasma. A potential new tumor marker? Br J Cancer 1995; 71:578-582.
3. Haglund C, Ylätupa S, Mertaniemi P, Partanen P. Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases. A comparison with CA 19-9 and CEA. Br J Cancer 1997; 76:777-783
4. Kanters SD, Banga JD, Algra A et al. Plasma levels of cellular fibronectin in diabetes. Diabetes Care 2001; 24: 323-7.
5. Serena J, Blanco M, Castellanos M et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005; 36: 1921-1926.
6. Castellanos M, Leira R, Serena J et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004; 35: 1671-6.
7. Castellanos M, Sobrino T, Millan M et al. Serum Cellular Fibronectin and Matrix Metalloproteinase-9 as Screening Biomarkers for the Prediction of Parenchymal Hematoma After Thrombolytic Therapy in Acute Ischemic Stroke. A Multicenter Confirmatory Study. Stroke 2007 May 3; [Epub ahead of print].
8. Honest H, Bachmann LM, Gupta JK et al. Accuracy of cervicovaginal fetal
fibronectin test in predicting risk of spontaneous preterm birth: systematic
review. BMJ. 2002; 325: 301-11.
9. Iams JD, Casal D, McGregor JA et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol 1995; 173: 141-5.
10. Joffe GM, Jacques D, Bemis-Heys R et al. Impact of the fetal fibronectin assay on admissions for preterm labor. Am J Obstet Gynecol 1999; 180: 581-6.
11. Peaceman AM, Andrews WW, Thorp JM et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol 1997; 177: 13-8.